Biomarin Pharmaceutical Inc (BMRN)
NASDAQ · Healthcare · Biotechnology
Biomarin Pharmaceutical Inc is a Healthcare company with a market capitalization of $11.40B and a trailing P/E ratio of 42.5.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 4, 2026 | $0.76 | $0.91 | -16.5% |
| Q4 2025 | February 23, 2026 | $0.46 | $0.81 | -43.5% |
| Q3 2025 | October 27, 2025 | $0.12 | $0.34 | -64.7% |
| Q2 2025 | August 4, 2025 | $1.44 | $1.03 | +39.8% |
| Q1 2025 | May 1, 2025 | $1.13 | $0.95 | +18.9% |
| Q4 2024 | February 19, 2025 | $0.92 | $0.74 | +24.6% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Biomarin Pharmaceutical Inc's market cap?
As of June 29, 2026, Biomarin Pharmaceutical Inc (BMRN) has a market capitalization of $11.40B.
What is Biomarin Pharmaceutical Inc's P/E ratio?
Biomarin Pharmaceutical Inc trades at a trailing price-to-earnings (P/E) ratio of 42.5. Its forward P/E is 11.9.
Does Biomarin Pharmaceutical Inc pay a dividend?
Biomarin Pharmaceutical Inc does not currently pay a dividend.
What sector is BMRN in?
Biomarin Pharmaceutical Inc is in the Healthcare sector, specifically the Biotechnology industry.
What was Biomarin Pharmaceutical Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Biomarin Pharmaceutical Inc reported revenue of $3.22B and net income of $348.90M.
Ask your own questions about BMRN
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.